Syros to Report First Quarter 2021 Financial Results on Thursday May 6, 2021
Syros Pharmaceuticals (NASDAQ:SYRS) will host a live conference call and webcast on May 6, 2021, at 8:30 a.m. ET to discuss its first-quarter financial results and provide a corporate update. Investors can join the call by dialing 866-595-4538 domestically or 636-812-6496 internationally, using conference ID 5770919. The event will also be available via webcast on their website, with an archive accessible for 30 days post-event. Syros is focused on gene expression control and has a strong clinical pipeline, including SY-1425 for myelodysplastic syndrome and SY-2101 for acute promyelocytic leukemia.
- Strong clinical-stage pipeline with significant potential in oncology.
- First-in-class oral selective RARα agonist (SY-1425) for higher-risk myelodysplastic syndrome.
- Novel oral arsenic trioxide (SY-2101) targeting acute promyelocytic leukemia.
- None.
Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Thursday, May 6, 2021 to report its first quarter 2021 financial results and provide a corporate update.
To access the live conference call, please dial 866-595-4538 (domestic) or 636-812-6496 (international), and refer to conference ID 5770919. A webcast of the call will also be available on the Investors & Media section of the Syros website at www.syros.com. An archived replay of the webcast will be available for approximately 30 days following the presentation.
About Syros Pharmaceuticals
Syros is redefining the power of small molecules to control the expression of genes. Based on its unique ability to elucidate regulatory regions of the genome, Syros aims to develop medicines that provide a profound benefit for patients with diseases that have eluded other genomics-based approaches. Syros is advancing a robust clinical-stage pipeline, including: SY-1425, a first-in-class oral selective RARα agonist in RARA-positive patients with higher-risk myelodysplastic syndrome and acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide in patients with acute promyelocytic leukemia; and SY-5609, a highly selective and potent oral CDK7 inhibitor in patients with select solid tumors. Syros also has multiple preclinical and discovery programs in oncology and monogenic diseases. For more information, visit www.syros.com and follow us on Twitter (@SyrosPharma) and LinkedIn.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210429005009/en/
FAQ
When is Syros Pharmaceuticals' first quarter 2021 earnings call?
How can I access the Syros Pharmaceuticals earnings call?
What is the focus of Syros Pharmaceuticals?
